Update on ARCA biopharma's Special Dividend
ARCA biopharma, Inc. (NASDAQ: ABIO) has shared important news regarding its upcoming merger with Oruka Therapeutics, Inc. As part of this significant transition, the company has announced a special cash dividend of $1.613 per share of its common stock. This announcement is a great opportunity for stockholders, showcasing ARCA’s dedication to enhancing shareholder value.
Special Dividend Details
The Board of Directors has declared this special dividend in relation to the merger agreement dated April 3, 2024. The amount of the special dividend has been calculated based on ARCA’s net cash position, which is expected to exceed $5,000,000 before the merger is finalized. This strategic decision underscores the company’s financial stability and health during a period of significant operational changes.
Important Ex-Dividend Date Information
Since the special dividend exceeds 25% of ARCA's stock price on the declaration date, it will activate specific regulations from The Nasdaq Stock Market LLC. As a result, the ex-dividend date has been established for one business day after the payment date, making August 29 particularly important for investors. Holders of ARCA common stock should carefully consider their trading positions during this timeframe.
What You Need to Know About the Due Bill Period
Investors who buy or sell ARCA common stock between August 25, 2024, and August 28, 2024, will have a due bill obligation. This means that buyers during this period will be eligible to receive the special dividend. It is essential for both buyers and sellers to understand these obligations, as they play a crucial role in how dividends are managed in stock transactions. ARCA encourages investors to consult with their brokers to fully grasp the details of these trading protocols.
Projected Closing Date of the Merger
The merger with Oruka is expected to close shortly after the distribution of the special dividend, around August 29, 2024. This timeline reflects ARCA's commitment to transparency and maintaining momentum during this transformative process. The merger represents a significant opportunity to combine strengths and enhance the capabilities of both organizations.
ARCA biopharma's Dedication to Innovation
ARCA biopharma remains committed to developing targeted therapies for cardiovascular diseases. The company emphasizes precision medicine in its drug development approach. Keeping investors informed about advancements and breakthroughs is vital to ARCA's strategy as they continue their pursuit of innovative healthcare solutions.
Overview of Oruka Therapeutics
Oruka Therapeutics shares ARCA's vision, focusing on developing groundbreaking biologics for chronic skin diseases. Their portfolio includes engineered antibodies that target key mechanisms behind conditions like plaque psoriasis. This mission to enhance treatment options aligns with the shared goal of improving patient outcomes, making this collaboration an exciting prospect for both companies.
Contact Information for Investor Relations
For inquiries related to the merger and the special dividend, investors can contact ARCA biopharma's investor relations representative, Jeff Dekker, at 720.940.2122 or via email at ir@arcabio.com. Additionally, Oruka Therapeutics can be reached through Alan Lada at 650.606.7911 or alan.lada@orukatx.com.
Frequently Asked Questions
What is the special dividend amount declared by ARCA biopharma?
The special dividend amount is $1.613 per share of ARCA’s common stock.
When is the ex-dividend date for the special dividend?
The ex-dividend date is set for August 29, 2024.
How does the due bill period affect ARCA’s stock transactions?
The due bill period affects trades between August 25, 2024, and August 28, 2024, determining who is entitled to the dividend.
What are the main goals of the merger with Oruka Therapeutics?
The merger aims to combine resources and enhance capabilities in developing innovative treatments for various diseases.
How can investors get more information about ARCA biopharma?
Investors can visit the company’s website or contact investor relations for more details.
